Xiao Ni | MD Anderson Cancer Center
Jan 8, 2024 · Associate Professor, Department of Dermatology - Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Associate …
Xiao Ni - Sarepta Therapeutics | LinkedIn
View Xiao Ni’s profile on LinkedIn, a professional community of 1 billion members. As the Head of Biometrics and a seasoned R&D analytics leader with 18 years of expertise…
- 500+ connections
- Location: Sarepta Therapeutics
Xiao Ni - Wikipedia
Xiao Ni (蕭嶷) (c. 444 [1] – 27 May 492 [2]), courtesy name Xuanyan (宣儼), formally Prince Wenxian of Yuzhang (豫章文獻王), was an imperial prince during the Chinese Southern Qi …
Xiao Ni - Google Scholar
Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary … X Ni, JL …
Dr. Xiao Ni - Directory - MD Anderson Cancer Center UTHealth …
My three ongoing research projects include: The main project is identifying and validating driver mutations and gene alternations for cutaneous T-cell lymphoma (CTCL). We are now working …
Ni Lab Members - MD Anderson Cancer Center
Dr. Xiao Ni earned her M.D. and Ph.D. in China, with research interests in T cell mediated skin diseases. Ni then completed her postdoctoral training in skin cancers, especially cutaneous T …
Xiao Ni - MD Anderson Cancer Center
Dive into the research topics where Xiao Ni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Xiao NI | Professor (Associate) | MD, PhD - ResearchGate
Xiao Ni Abstract: Cutaneous T-Cell Lymphomas (CTCLs) are lymphoproliferative diseases affecting skin-homing cells, and Mycosis Fungoides (MF) and Sézary Syndrome (SS) are the …
Xiao Ni - Executive Director Biostatistics at Sarepta Therapeutics
Mar 25, 2024 · View Xiao Ni's email address (x*****@sarep***.com) and phone number. Xiao works at Sarepta Therapeutics as Executive Director Biostatistics. Xiao is based out of …
Xiao NI | Research profile
Aim: To provide a descriptive comparison of erectile function response for tadalafil on-demand (PRN) and once-daily (OAD) dosing regimens in patients with common comorbid conditions,...
- Some results have been removed